Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme built from two nucleotides joined through their phosphate groups. A peptide is a chain of amino acids linked by peptide bonds, and NAD+ contains no amino acids at all. The confusion is understandable: clinics and online vendors list NAD+ next to BPC-157, epitalon and SS-31, sell it in the same small vials, and inject it with the same needles. That is a retail category, not a chemical one. This article explains what NAD+ actually is, what the body uses it for, what the small human studies of injected and intravenous NAD+ have measured, and how NAD+ differs from SS-31, a real peptide that also targets the mitochondria and is often sold alongside it. It is educational background on published research, not medical advice or a recommendation to take anything.
Key Takeaways: Is NAD+ a Peptide?
NAD+ is not a peptide. NAD+ is nicotinamide adenine dinucleotide, a coenzyme with the formula C21H28N7O14P2 and a molecular weight of 664.43 according to the KEGG compound database. The two phosphorus atoms in NAD+ come from the phosphate groups that link its two nucleotides. Peptides are built from amino acids and do not carry that phosphate backbone. SS-31, sold as the drug elamipretide, is a genuine peptide. Its prescribing information lists the sequence D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2 and the formula C32H49N9O5, with no phosphorus. NAD+ is used by the body as a coenzyme for energy-producing redox reactions and as a fuel for sirtuins, CD38 and PARP enzymes, according to a 2021 review in Nature Reviews Molecular Cell Biology. The human evidence for injected or infused NAD+ is very thin. A 2019 pilot study gave 750 mg of NAD+ intravenously to 8 men and found that plasma NAD+ did not rise at all for the first 2 hours. A 2026 review of clinic records found that all 6 clients given 500 mg NAD+ drips reported moderate to severe symptoms during the infusion.
Is NAD+ a peptide or a coenzyme?
NAD+ is a coenzyme, not a peptide. The name spells out the structure: nicotinamide adenine dinucleotide. One nucleotide carries nicotinamide, a form of vitamin B, and the other carries adenine, the same base found in DNA and ATP. The two halves are joined through a pair of phosphate groups. A peptide is a different kind of molecule. Peptides are short chains of amino acids, the building blocks of proteins, held together by peptide bonds. Epitalon is a chain of four amino acids. SS-31 is also a chain of four amino acids. Semaglutide is a much longer chain. NAD+ has no amino acids and no peptide bonds, so by any chemistry textbook definition it does not qualify. The atom count makes the difference visible. KEGG lists NAD+ as C21H28N7O14P2, which means 21 carbon, 28 hydrogen, 7 nitrogen, 14 oxygen and 2 phosphorus atoms. The FORZINITY label lists elamipretide, the drug form of SS-31, as C32H49N9O5: more carbon and hydrogen, no phosphorus. The phosphorus in NAD+ is the fingerprint of a nucleotide.
NAD+ Carries Phosphorus. A Peptide Does Not.
Atoms per molecule by element. NAD+ (C21H28N7O14P2, KEGG COMPOUND C00003) holds two phosphate groups; elamipretide, a true tetrapeptide (C32H49N9O5, FORZINITY prescribing information), has none.
- NAD+ (coenzyme)
- Elamipretide / SS-31 (peptide)
Why is NAD+ called a peptide?
NAD+ gets called a peptide because of how it is sold, not because of what it is. Wellness clinics and research-chemical vendors group NAD+ with peptides because the products look and are handled alike: a lyophilized powder or solution in a small vial, mixed and injected under the skin or given by drip, often in the same longevity or recovery package. Size adds to the confusion. NAD+ has a molecular weight of 664.43 according to KEGG. Elamipretide hydrochloride, the salt form used in the approved drug, has a molecular weight of 749.2 according to its label. Two molecules of similar size can belong to completely different chemical families, and molecular weight says nothing about whether a molecule is built from amino acids. The practical consequence is that the term NAD+ peptide tells a buyer nothing useful. A man who sees NAD+ on a peptide menu should read it as a separate compound with its own, very different evidence base.
Similar Size, Different Chemistry
Molecular weight in g/mol. NAD+ from KEGG COMPOUND C00003; elamipretide as its hydrochloride salt from the FORZINITY prescribing information. Size alone does not make a molecule a peptide.
What is NAD+ used for in the body?
NAD+ is used in the body for two broad jobs: moving electrons in energy metabolism and serving as a fuel for signalling enzymes. A 2021 review by Covarrubias, Perrone, Grozio and Verdin in Nature Reviews Molecular Cell Biology describes NAD+ as a coenzyme for redox reactions, central to energy metabolism, and as an essential cofactor for sirtuins, CD38 and poly(ADP-ribose) polymerases, the PARP enzymes involved in DNA repair. The redox role works like a shuttle. NAD+ picks up electrons when cells break down glucose and fat, becoming NADH, and hands them to the mitochondria, where they drive ATP production. The signalling role is different: sirtuins, CD38 and PARPs consume NAD+ outright, which is one reason cells must keep remaking it. The same review states that tissue and cellular NAD+ levels decline gradually with age in rodents and humans, and that much remains to be learned about whether restoring NAD+ is safe and beneficial in ageing people. That caveat comes from researchers who work in the field and have commercial ties to NAD+ companies, which the paper discloses.
What is NAD+ peptide used for in clinics?
What clinics sell as an NAD+ peptide is usually NAD+ itself, given by intravenous drip or by injection under the skin, marketed for energy, recovery and healthy ageing. The published human data cover intravenous NAD+ only, in a few small pilot studies; we found no published human study of NAD+ injected under the skin. None of the infusion studies tested energy, recovery or ageing outcomes in a controlled way. Most NAD+ research in people has used oral precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body converts into NAD+. Those trials, covered in our separate review of NAD+ precursor evidence, show reliable rises in blood NAD+ and far fewer clear clinical benefits. Direct NAD+ infusion has even less behind it. Grant and colleagues, writing in Frontiers in Aging Neuroscience in 2019, stated that no data were available on the fate of directly infused NAD+ in a human cohort before their study. Their pilot was the first to measure it.
What happens to NAD+ when it is infused?
When NAD+ is infused into a vein, it is cleared from the blood quickly at first, and plasma levels do not rise for some time. Grant and colleagues gave 11 men aged 30 to 55 either 750 mg of NAD+ (8 men) or saline (3 men) over 6 hours, an infusion rate of about 2 mg/min, or 3 μmol/min. Plasma NAD+ did not change at all for the first 2 hours. The authors concluded that at this rate, NAD+ was rapidly and completely removed from plasma during that window. Only at 6 hours, the end of the infusion, did plasma NAD+ and its breakdown products reach roughly 400% above baseline. Urine at 6 hours contained NAD+ itself and methylnicotinamide, a waste product, which means part of the dose was excreted. No adverse events were observed in either group. Two points limit how far the result travels. The study enrolled only 8 men on NAD+, and two authors were affiliated with NAD+ Research Inc. and the Springfield Wellness Center, a clinic that offers NAD+ infusions. The paper measured where NAD+ went in blood and urine, not whether anyone felt or functioned better.
Infused NAD+ Vanished From Plasma for Two Hours
Approximate rise in plasma NAD+ above baseline during a 750 mg intravenous infusion over 6 hours in 8 men. No change was seen until after 2 hours; the peak of about 400% came only at 6 hours (Grant and colleagues, Frontiers in Aging Neuroscience, 2019).
Is IV NAD+ well tolerated?
IV NAD+ was poorly tolerated at clinic speeds in the one study that recorded symptoms. Reyna and colleagues, Frontiers in Aging, 2026, reviewed records from a commercial wellness clinic where clients received 500 mg of NAD+ or 500 mg of nicotinamide riboside by drip on 4 consecutive days, with 30 days of follow-up. Six clients received NAD+ and 8 received NR. All 6 NAD+ clients reported moderate to severe symptoms during the drip, including abdominal cramping, nausea, diarrhoea, a faster heart rate and chest pressure. The symptoms resolved when the infusion stopped. Because clients slowed the drip when they felt unwell, NAD+ infusions averaged 97 minutes against 37 minutes for NR. Liver, kidney, thyroid and inflammation markers did not change significantly, but HDL cholesterol fell significantly in the NAD+ group over the 30 days. This is weak evidence by design: a retrospective chart review of 14 people, no placebo, and every author employed by the clinic chain. It does give a realistic picture of what a clinic drip can feel like, which is more than the marketing usually offers.
NAD+ Drips Ran Longer Because People Could Not Tolerate Them Faster
Average infusion time in minutes over 4 consecutive days, 6 clients on NAD+ and 8 on nicotinamide riboside. Every NAD+ client reported moderate to severe symptoms during infusion. Retrospective clinic records, no placebo, authors employed by the clinic (Reyna and colleagues, Frontiers in Aging, 2026).
What is the difference between SS-31 and NAD+?
The difference between SS-31 and NAD+ is that SS-31 is a peptide drug that binds a mitochondrial membrane lipid, while NAD+ is a coenzyme that carries electrons into the mitochondrial energy chain. They act on the same organelle in different ways. SS-31 is elamipretide. Its label describes it as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial structure and function. Cardiolipin is a fat in that membrane that holds the energy-producing machinery in place. Elamipretide is an FDA-approved drug, sold as FORZINITY, for one narrow use: to improve muscle strength in people with Barth syndrome who weigh at least 30 kg, under accelerated approval. The recommended dose is 40 mg injected under the skin once daily. Our separate review of SS-31 safety covers the injection site reactions and allergy warning on that label. NAD+ is not an FDA-approved drug for any indication we could find. It is a molecule the body already makes and recycles, and the human dosing data come from small clinic studies of 500 mg and 750 mg drips. The scale is different too: the approved SS-31 dose is 40 mg, while the NAD+ infusions studied used 500 mg to 750 mg per session.
The Doses Are Not in the Same League
Milligrams per dose. Elamipretide from the FORZINITY label (40 mg subcutaneously once daily); NAD+ from Reyna and colleagues, 2026 (500 mg IV) and Grant and colleagues, 2019 (750 mg IV over 6 hours). Different routes and purposes; shown only to contrast scale.
Can SS-31 and NAD+ be taken together?
No published human trial has tested SS-31 and NAD+ together, so the safety and effect of the combination are unknown. A PubMed search for elamipretide or SS-31 with NAD+ in human studies returned reviews and laboratory work, not a combined treatment trial. The closest data come from heart tissue in a lab. Nollet and colleagues, European Heart Journal, 2023, studied septal muscle removed during surgery from 59 patients with hypertrophic cardiomyopathy. Mitochondria in that tissue showed impaired NADH-linked respiration, the step where electrons carried by NAD+ feed the energy chain. Pre-incubating the tissue with elamipretide boosted that respiration, and so did raising mitochondrial NAD+ levels. The two approaches were tested side by side on tissue samples, not combined, and not given to patients. That finding explains why the pairing appeals to people: both act on the same energy pathway from different angles. It does not show that injecting both helps anyone. Anyone considering either compound should discuss it with a physician who can review the full medication list.
What should a man take away from the NAD+ peptide question?
A man researching NAD+ should take away that NAD+ is not a peptide and should be judged on its own evidence. NAD+ is a coenzyme made of two nucleotides, with phosphate groups no peptide carries, and the peptide label comes from how clinics package it. The NAD+ evidence that exists points in two directions. The biology is well established: NAD+ is central to energy metabolism and DNA repair, and levels fall with age. The evidence for injecting or infusing NAD+ is not: one pilot of 8 men tracked where an infusion went, and one chart review of 6 clients documented how uncomfortable fast drips can be. Neither tested an outcome a buyer actually cares about. SS-31 is the real peptide in this conversation, with a narrow FDA approval and its own safety record. Treating NAD+ as one more peptide on the same menu hides how differently the two compounds have been studied.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
What Is the Difference Between Peptides and Copper Peptides? A Copper Peptide Is a Peptide Holding a Metal Ion, and the Skin Evidence Splits Along That Line
What is the difference between peptides and copper peptides? A copper peptide is a peptide bound to copper. How GHK-Cu differs and what skin trials show.